je.st
news
Tag: merck
Merck, Intel lift Dow overnight
2013-06-04 07:31:06| Biotech - Topix.net
The Dow Jones Industrial Average advanced overnight, boosted by shares of Merck and Intel, though disappointing manufacturing data kept a lid on gains.
Tags: intel
lift
overnight
dow
At midday: S&P dips; Merck lifts Dow
2013-06-04 03:16:29| Biotech - Topix.net
U.S. stocks were mostly lower in choppy trade on Monday as the latest data on manufacturing continued to paint a mixed picture on the strength of the economy.
Shares of Merck, Bristol jump on cancer drug news
2013-06-03 23:06:59| Biotech - Topix.net
Shares of Bristol-Myers Squibb Inc. and Merck & Co. are up about 5 percent each after the drugmakers announced encouraging results on experimental cancer medicines over the weekend.
Merck melanoma drug shrinks tumors in 38 percent of patients
2013-06-02 18:54:47| Biotech - Topix.net
A Merck & Co drug designed to unmask tumor cells and mobilize the immune system into fighting cancer helped shrink tumors in 38 percent of patients with advanced melanoma in an early-stage study, U.S. researchers said on Sunday.
Tags: of
drug
percent
patients
Merck Announces Presentation of Interim Data from Study Evaluating Lambrolizumab, an Investigational Anti-PD-1 Antibody, in Patients with Advanced Melanoma at ASCO 2013
2013-06-02 17:15:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. -Merck Expands Lambrolizumab Clinical Development Program- -Study Published Online in the New England Journal of Medicine- WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the presentation of preliminary results from an ongoing Phase IB expansion study evaluating the safety and efficacy of lambrolizumab (MK-3475), Mercks investigational antibody therapy targeting PD-1, in patients with advanced (inoperable and metastatic) melanoma. Language: English Contact HTML: MerckMedia Contacts:Ian McConnell, 973-901-5722Cathy Cantone, 908-327-3013orInvestor Contacts:Carol Ferguson, 908-500-1101Justin Holko, 609-915-8293 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: data
advanced
study
presentation
Sites : [112] [113] [114] [115] [116] [117] [118] [119] [120] [121] [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] next »